Halozyme (HALO) Form 144: Helen Torley Recent Sales and Proposed 136,569-Share Sale

Rhea-AI Filing Summary

Halozyme Therapeutics (HALO) Form 144 notice reports a proposed sale of 136,569 shares of common stock through J.P. Morgan Securities, with an aggregate market value reported as $10,015,970 and an approximate sale date of 10/01/2025 on NASDAQ. The filing shows the shares were acquired on 10/01/2025 via stock option exercise and paid in cash. Recent disclosed sales by the same person, Helen Torley, list nine separate transactions from 07/08/2025 through 09/04/2025, each of 20,000 shares, with gross proceeds shown for each trade.

Positive

• Transparent disclosure of broker (J.P. Morgan Securities) and planned sale date
• Detailed history of recent sales by Helen Torley with dates and gross proceeds

Negative

• No indication of a 10b5-1 trading plan or plan adoption date in the filing
• Large insider sale (136,569 shares, $10.02M value) could be perceived negatively by some investors

Insights

Securities Analyst

TL;DR: Insider plans a large sale following option exercise; prior periodic disposals occurred over July–September 2025.

The Form 144 documents a proposed sale of 136,569 common shares executed through J.P. Morgan, valued at $10.0 million. The shares were acquired the same day by stock option exercise and paid for in cash, indicating a typical post-exercise transfer rather than a secondary transfer from a separate acquisition. Helen Torley's listed prior sales show routine disposition of 20,000-share blocks across nine dates, producing multi-hundred-thousand-dollar proceeds per trade. This filing is procedural under Rule 144 and discloses the timing and scale of insider sales but does not include any nonpublic operational or financial information.

Corporate Governance Expert

TL;DR: Disclosure aligns with Rule 144 requirements; no stated material nonpublic information is claimed.

The notice contains required representations about absence of undisclosed material adverse information and notes the signature attestation. The reported acquisition via option exercise and immediate proposed sale is consistent with executives monetizing vested equity. The filing does not provide context on any insider trading plans or 10b5-1 arrangements (no plan adoption date provided), so reviewers must rely solely on the stated transactions. From a governance perspective, transparent timing and broker identification (J.P. Morgan Securities) meet typical disclosure expectations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	J.P. Morgan Securities LLC 390 Madison Avenue - 6th Floor New York NY 10017	136569	10015970	116966000	10/01/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	10/01/2025	Stock Option Exercise	Issuer			136569	10/01/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Helen Torley C/o Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130	Common Stock	07/08/2025	20000	1110239
Helen Torley C/o Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130	Common Stock	07/09/2025	20000	1128657
Helen Torley C/o Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130	Common Stock	07/10/2025	20000	1148617
Helen Torley C/o Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130	Common Stock	08/11/2025	20000	1260922
Helen Torley C/o Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130	Common Stock	08/12/2025	20000	1270123
Helen Torley C/o Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130	Common Stock	08/13/2025	20000	1286349
Helen Torley C/o Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130	Common Stock	09/02/2025	20000	1475123
Helen Torley C/o Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130	Common Stock	09/03/2025	20000	1488731
Helen Torley C/o Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130	Common Stock	09/04/2025	20000	1480769

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does HALO Form 144 report?

The filing reports a proposed sale of 136,569 Halozyme common shares through J.P. Morgan Securities, with an aggregate market value of $10,015,970 and an approximate sale date of 10/01/2025.

How were the 136,569 shares acquired according to the filing?

The shares were acquired on 10/01/2025 by stock option exercise from the issuer and payment was made in cash on that date.

Who has been selling Halozyme shares recently according to the filing?

The filing lists Helen Torley selling nine blocks of 20,000 shares each between 07/08/2025 and 09/04/2025, with gross proceeds shown for each trade.

Does the filing state whether a 10b5-1 plan was used?

No; the filing does not provide a plan adoption date or indicate reliance on a Rule 10b5-1 trading plan.

Which broker is handling the proposed sale?

The proposed sale is reported to be handled by J.P. Morgan Securities LLC (390 Madison Avenue, New York).